Diasorin SpA (DSRLF) Full Year 2024 Earnings Call Highlights: Resilient Performance Amid Global ...
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Diasorin SpA (DSRLF) reported revenue and profitability in line with their plan, budget, and guidance for 2024, despite geopolitical tensions.
The company successfully launched the Liaison Complex with respiratory panels, leading to better-than-expected performance in the molecular segment.
Diasorin SpA (DSRLF) raised its guidance twice in 2024, indicating strong performance and confidence in their business strategy.
The US hospital strategy is working well, with the company achieving its target of serving 400 hospitals by year-end.
The company experienced double-digit growth in Europe, driven by successful placements and increasing volumes.
Diasorin SpA (DSRLF) continues to face difficulties in China, with double-digit revenue decreases due to local competition and economic conditions.
COVID-19 testing revenues have significantly decreased, impacting overall revenue growth.
The company faces tough competition in certain markets, such as Iran, affecting export revenues.
There is a mild start to the flu season, which has impacted the molecular diagnostics segment.
The company is experiencing inflationary pressures and increased manufacturing costs, particularly in their new Shanghai plant.
Warning! GuruFocus has detected 5 Warning Signs with DSRLF.
Q: Can you elaborate on the guidance for 2025, considering the headwinds like European immuno diagnostics and China? Does your guidance imply a 9-10% underlying growth excluding these factors? Also, how does the Liaison XXL expand your addressable market in the US? A: The XXL system is designed to protect our existing install base while expanding into hospital and laboratory markets. It offers a 30-35% increase in throughput, allowing us to serve both large commercial labs and hospital markets. Excluding China, we expect double-digit growth in the US and high single-digit growth in Europe for 2025.
Q: How do you navigate the US market given the potential impacts from tariffs, vaccination hesitancy, and NIH budget cuts? Also, what is your outlook for China with a broader product portfolio by 2026? A: Decreased vaccination rates could lead to outbreaks, which may benefit our diagnostics business. We haven't seen significant impacts from NIH budget cuts yet. For China, while it's not strategic in the short term, having products manufactured locally positions us well if the market improves.
Q: Could you clarify the target for Liaison Plex customers by the end of 2025? You mentioned both 100 and 150 customers. A: Both numbers are correct. We have a funnel of 100 customers corresponding to 500 systems. Our ambition for 2025 is to have 150 customers using our platforms, aiming for a multiplexing business growth to 75 million, representing a 25% increase from 2024.
Q: What is the expected impact of VBP in China for 2025, and how do you see the immuno business growth drivers? A: The VBP impact in China is expected to be 5-6 million in 2025. For the immuno business, growth is driven by a diverse portfolio, including Quantiferon, stool diagnostics, and infectious disease panels, with significant interest in our M product.
Q: How do you anticipate the LTG business performing, given the recovery in life sciences and biopharma segments? A: The LTG business is expected to grow below the overall 8% guidance for 2025. We see recovery in life sciences and biopharma, with diagnostics representing 50% of the LTG business, providing stability against life sciences headwinds.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 minutes ago
- Business Upturn
Liverpool in advanced talks to sign Parma's Giovanni Leoni immediately
By Ravi Kumar Jha Published on August 13, 2025, 19:11 IST Liverpool are pushing to secure the signing of highly-rated Italian defender Giovanni Leoni from Parma, with negotiations now at an advanced stage. According to transfer expert Fabrizio Romano, the Premier League club are working to complete the move immediately rather than waiting until the summer of 2026. The 18-year-old centre-back has emerged as one of Italy's brightest defensive prospects, attracting attention from several top European clubs. However, Liverpool have moved swiftly to bring him in as part of Arne Slot's squad for the remainder of the season, with no plans to loan him back to Italy. Sources indicate that Leoni has already given the green light to the move, expressing enthusiasm for joining Liverpool's long-term project. Club-to-club talks between Liverpool and Parma are ongoing, and optimism is growing that a deal could be finalized soon. Leoni's arrival would represent a significant investment in youth for Liverpool, who continue to blend emerging talent with established stars. With injuries affecting their defensive options this season, the acquisition of a versatile, composed young defender could provide both immediate depth and a long-term solution at the back. Arne Slot is understood to be keen on integrating Leoni straight into first-team training upon his arrival, offering the teenager a unique opportunity to develop alongside experienced players in one of the most competitive leagues in the world. Ahmedabad Plane Crash Ravi kumar jha is an undergraduate student in Bachelor of Arts in Multimedia and Mass Communication. A media enthusiast who has a strong hold on communication and he also has a genuine interest in sports. Ravi is currently working as a journalist at
Business Wire
30 minutes ago
- Business Wire
StatLab Empowers Growth in Key European Countries through Direct Market Expansions in Germany and France
MCKINNEY, Texas--(BUSINESS WIRE)--StatLab Medical Products ('StatLab'), a leading global developer and manufacturer of medical diagnostic supplies and equipment, today announced the completed acquisitions of Germany-based histology service and distribution company Histoserve GmbH ('Histoserve') as well as Diapath France SAS ('Diapath France'). These moves mark a significant step forward in StatLab's European growth strategy, expanding its direct commercial presence to the top four European markets: France, Germany, Italy, and the UK, a milestone that positions StatLab among the few suppliers with fully direct access to Europe's largest pathology markets, enabling closer customer relationships and expanded access to StatLab's full product portfolio. This milestone positions StatLab among the few suppliers with direct access to Europe's largest pathology markets, enabling closer customer relationships and expanded access to StatLab's full product portfolio. Share Founded by Wolfgang Jakobi in 2010 near Hannover, Germany, Histoserve has evolved into a comprehensive solutions provider for pathology labs, providing reliable reagents, innovative instrumentation through Diapath, and best-in-class post-sales support. Diapath made a strategic majority investment in Histoserve in 2021 to create a regional hub and direct market access in Germany. With deep equipment service expertise and strong customer ties, Histoserve will play a critical role in expanding market access to the entire StatLab portfolio in Europe's largest market. In parallel, StatLab acquired the remaining stake in Diapath France—a joint venture formed in 2023 between Diapath and Jacques Hannaby to serve the direct laboratory market in France. These additions strengthen StatLab's direct footprint and future scalability in France and Germany while complementing its already established presence in the UK and Italy, and provide the platform to create an industry leader across the four largest European markets and beyond. 'We're thrilled to officially welcome Histoserve and Diapath France into the StatLab family,' said Alberto Battistel, Managing Director of Diapath. 'Although we've collaborated with Wolfgang and Jacques for several years, fully integrating their businesses into our European strategic plan will further strengthen customer relationships and fuel additional growth.' 'The evolution of the StatLab organization has been exciting to witness, and we're proud to now be a full part of their differentiated solution as a result of the completed acquisition,' said Wolfgang Jakobi, founder of Histoserve. 'Our customers will gain access to a broader product portfolio, and together we'll deliver a more unified customer experience, supporting growth with direct labs across Germany and Northern Europe.' About StatLab Medical Products StatLab Medical Products has been dedicated to helping anatomic pathology laboratories provide the best possible patient care since 1976. We offer an extensive portfolio of self-manufactured consumables and equipment from nine manufacturing sites across the United States, United Kingdom, and Europe. Our global operational footprint powered by over 800 mission-driven colleagues delivers a dependable and resilient supply chain of high-quality products and solutions, and a customer-centric approach inspires us to deliver reliability, innovation, and quality in every interaction. About Histoserve Established in Celle, near Hannover, Germany, Histoserve GmbH has delivered decades of histology equipment service—including installation, maintenance, repair, and supply of new and refurbished instruments. With ISO 9001-certified support and a long-standing customer base across Germany and Northern Europe, the company now joins the StatLab family via Diapath to expand its direct-lab service and equipment portfolio.
Business Insider
2 hours ago
- Business Insider
The latest Millennium spin-out is a new credit hedge fund seeded by a $6 billion backer
Ryan Foster is launching Extant Capital with $200 million from New Holland Capital, a $6 billion alternative investor that invests in external funds, according to the firm. Foster most recently worked as a senior portfolio manager at Torsion Capital, a team within Izzy Englander's $78 billion Millennium, where he traded for six years. Prior to Millennium, he spent nine years as a credit investor for George Soros' firm. The firm will focus on credit markets, and its day-one roster includes Peter Ellingboe as a senior portfolio manager. Ellingboe previously worked as a portfolio manager for Walleye, which he joined last year, and Verition, where he spent more than five years. "Ryan is a highly skilled credit manager with a strong track record in constructing credit-focused absolute return strategies that provide unique exposure to dislocations within the market," said Scott Radke, New Holland's CEO and co-CIO, in the release. Extant is the latest addition to New Holland's roster of external money managers, which now numbers more than 40. Firms backed by the New York-based firm include former Bridgewater executive Paul Podolsky's Kate Capital, Centiva's onetime European credit head Terrence Matthews' Athlone Investment Management, and ex-Eisler volatility portfolio manager Hardeep Jutti's new fund. New Holland started as an investment advisor for Dutch pension plans and has since become independent. While the firm expects a majority of its investments to continue to be in externally run managers, New Holland is building up its internal team of traders, Radke told Business Insider in July. The firm's new unit, Plum Island, will focus on money managers who do not want to run their own company and has hired former North Rock Capital COO Omar Qaiser to lead it. Foster is the latest Millennium portfolio manager to start his own firm. Some of the industry's most notable launches in recent years include alumni of Englander's manager, such as his former chief investment officer Bobby Jain, the founder of Jain Global, and Diego Megia, who started London-based Taula Capital with money from Millennium.
